Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Nov 26, 2014; 6(5): 511-525
Published online Nov 26, 2014. doi: 10.4252/wjsc.v6.i5.511
Histone modifications: Targeting head and neck cancer stem cells
John M Le, Cristiane H Squarize, Rogerio M Castilho
John M Le, Cristiane H Squarize, Rogerio M Castilho, Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109-1078, United States
Author contributions: Le JM, Squarize CH and Castilho RM contributed equally to this work; all authors were involved in reviewing the literature and writing the manuscript.
Supported by University of Michigan, School of Dentistry startup
Correspondence to: Rogerio M Castilho, DDS, MS, PhD, Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 N University Ave, Room 3323B, Ann Arbor, MI 48109-1078, United States. rcastilh@umich.edu
Telephone: +1-734-6472150 Fax: +1-734-7635503
Received: August 29, 2014
Revised: September 10, 2014
Accepted: September 17, 2014
Published online: November 26, 2014
Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and is responsible for a quarter of a million deaths annually. The survival rate for HNSCC patients is poor, showing only minor improvement in the last three decades. Despite new surgical techniques and chemotherapy protocols, tumor resistance to chemotherapy remains a significant challenge for HNSCC patients. Numerous mechanisms underlie chemoresistance, including genetic and epigenetic alterations in cancer cells that may be acquired during treatment and activation of mitogenic signaling pathways, such as nuclear factor kappa-light-chain-enhancer-of activated B cell, that cause reduced apoptosis. In addition to dysfunctional molecular signaling, emerging evidence reveals involvement of cancer stem cells (CSCs) in tumor development and in tumor resistance to chemotherapy and radiotherapy. These observations have sparked interest in understanding the mechanisms involved in the control of CSC function and fate. Post-translational modifications of histones dynamically influence gene expression independent of alterations to the DNA sequence. Recent findings from our group have shown that pharmacological induction of post-translational modifications of tumor histones dynamically modulates CSC plasticity. These findings suggest that a better understanding of the biology of CSCs in response to epigenetic switches and pharmacological inhibitors of histone function may directly translate to the development of a mechanism-based strategy to disrupt CSCs. In this review, we present and discuss current knowledge on epigenetic modifications of HNSCC and CSC response to DNA methylation and histone modifications. In addition, we discuss chromatin modifications and their role in tumor resistance to therapy.

Keywords: Head and neck squamous cell carcinoma, Chromatin remodeling, Histone deacetylases inhibitor, Histone acetylation, Cancer-initiating cell, Epigenetic target, Epigenetic marker, Oral squamous cell carcinoma, Tumor resistance

Core tip: Stem cells are long-lived, therefore their genome is subject to more stress from genetic mutations and epigenetic factors than their short-lived, differentiated progeny. Recent evidence strongly indicates that a subpopulation of tumor initiating cells, termed “cancer stem cells”, play a fundamental role in tumor heterogeneity, growth, and preservation. Cancer stem cell behavior is influenced by epigenetic events comprised primarily of DNA methylation and histone modifications that dynamically regulate gene expression and silencing.